Skip to main content
SpringerLink
Log in

De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

To determine the prognostic impact of de novo deletion 17p13.1 (17p–) in previously untreated chronic lymphocytic leukemia (CLL) patients, we prospectively studied the outcome of 71 treatment-naïve CLL patients. About 18.3 % of them had 17p– detected by interphase fluorescent in situ hybridization (FISH) at diagnosis. There was statistically significant difference between 17p– negative and positive patients as regards 2-year overall survival [OS] (89.7 vs. 53.8 %, respectively; P = 0.001). On the other hand, 2-year progression-free survival [PFS] was also significantly higher in 17p– negative group than in 17p– positive one (82.8 vs. 23.1 %, respectively; P < 0.001). On univariate analysis for OS, 17p– positivity was significantly associated with shorter OS (P = 0.003). However, when we performed multivariate analysis, 17p– lost its significant impact. On the other hand, 17p– positivity was a significant risk factor for PFS in both univariate and multivariate analyses [independent risk factor] (P < 0.001 and P = 0.02, respectively). So, 17p– is a predictor for disease progression, but not for survival in CLL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematol Am Soc Hematol Educ Progr. 2013;2013:138–50.

    Article  Google Scholar 

  2. Hallek M. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol. 2008;19(Supplement 4):iv51–3.

    Article  PubMed  Google Scholar 

  3. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 Trial. J Clin Oncol. 2011;29(16):2223–9.

    Article  PubMed  Google Scholar 

  4. Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: What’s ready for prime time use? Haematologica. 2010;95(1):12–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994–4001.

    Article  CAS  PubMed  Google Scholar 

  6. Zainuddin N, Murray F, Kanduri M, et al. TP53 mutations are infrequent in newly-diagnosed chronic lymphocytic leukemia. Leuk Res. 2011;35(2):272–4.

    Article  CAS  PubMed  Google Scholar 

  7. Foà R, Del Giudice I, Guarini A, et al. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013;98(5):675–85.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lin K, Adamson J, Johnson GG, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res. 2012;18:4191–200.

    Article  CAS  PubMed  Google Scholar 

  9. Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862–73.

    Article  CAS  PubMed  Google Scholar 

  10. Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematol Am Soc Hematol Educ Progr. 2011;2011:104–9.

    Article  Google Scholar 

  11. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114:957–64.

    Article  CAS  PubMed  Google Scholar 

  12. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23:212–4.

    Article  CAS  PubMed  Google Scholar 

  13. Pei J, Jhanwar SC, Testa JR. Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leuk Res Rep. 2012;1:4–6.

    PubMed  PubMed Central  Google Scholar 

  14. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 2002;116:142–50.

    Article  CAS  PubMed  Google Scholar 

  16. Delgado J, Espinet B, Oliveira AC, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol. 2012;157:67–74.

    Article  CAS  PubMed  Google Scholar 

  17. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580–9.

    CAS  PubMed  Google Scholar 

  18. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    Article  CAS  PubMed  Google Scholar 

  19. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–6.

    CAS  PubMed  Google Scholar 

  20. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177–84.

    CAS  PubMed  Google Scholar 

  21. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol. 2003;121:287–95.

    Article  PubMed  Google Scholar 

  22. Xu W, Li JY, Li L, et al. Fluorescent in situ hybridization with a panel of probes detects molecular cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Zhonghua Yi Xue Za Zhi. 2008;88(36):2537–40.

    PubMed  Google Scholar 

  23. Michalová K, Zemanová Z, Cmunt E, et al. The interphase fluorescence in situ hybridization (I-FISH) technique in patients with chronic lymphatic leukemia (CLL). Cas Lek Cesk. 2000;139(11):334–8.

    PubMed  Google Scholar 

  24. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup Phase III trial E2997. J Clin Oncol. 2007;25(7):799–804.

    Article  CAS  PubMed  Google Scholar 

  25. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589–97.

    Article  CAS  PubMed  Google Scholar 

  26. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–9.

    Article  PubMed  Google Scholar 

  27. CLL Trialists’ Collaborative Group. (CLLTCG). Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica. 2012;97(3):428–36.

    Article  Google Scholar 

  28. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Parikh SA, Keating MJ, O’Brien S, et al. Frontline chemoimmuno-therapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23:1779–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia With 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26(13):5094–100.

    Article  PubMed  Google Scholar 

  33. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplantation Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Amro M. S. El-Ghammaz, Essam Abdelwahed, Nevine N. Mostafa & Dina A. Mansour

Authors
  1. Amro M. S. El-Ghammaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Essam Abdelwahed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nevine N. Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dina A. Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amro M. S. El-Ghammaz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Ghammaz, A.M.S., Abdelwahed, E., Mostafa, N.N. et al. De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. Clin Exp Med 15, 493–499 (2015). https://doi.org/10.1007/s10238-014-0317-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-014-0317-2

Keywords

Search

Navigation